Volume | 188,519 |
|
|||||
News | - | ||||||
Day High | 3.89 | Low High |
|||||
Day Low | 3.764 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Theseus Pharmaceuticals Inc | THRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.82 | 3.764 | 3.89 | 3.86 | 3.81 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,551 | 188,519 | $ 3.84 | $ 723,994 | - | 2.05 - 14.7672 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:55:50 | formt | 1,239 | $ 3.86 | USD |
Theseus Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
170.73M | 44.23M | - | 0 | -50.61M | -1.14 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Theseus Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical THRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.50 | 3.9348 | 3.46 | 3.76 | 737,853 | 0.36 | 10.29% |
1 Month | 2.28 | 3.9348 | 2.05 | 3.26 | 1,716,581 | 1.58 | 69.3% |
3 Months | 3.00 | 3.9348 | 2.05 | 3.19 | 614,801 | 0.86 | 28.67% |
6 Months | 7.27 | 10.87 | 2.05 | 3.73 | 627,852 | -3.41 | -46.91% |
1 Year | 6.60 | 14.7672 | 2.05 | 5.17 | 419,829 | -2.74 | -41.52% |
3 Years | 20.80 | 24.54 | 2.05 | 6.82 | 262,881 | -16.94 | -81.44% |
5 Years | 20.80 | 24.54 | 2.05 | 6.82 | 262,881 | -16.94 | -81.44% |
Theseus Pharmaceuticals Description
Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. |